CK-0802 is under clinical development by Cellenkos and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Ibudilast is under clinical development by MediciNova and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

The association between age and 90-day mortality in acute respiratory distress syndrome was nonlinear. The risk for death stayed elevated after a patient turned 65 years old but rose in a slower ...

As India logs 5 cases of HMPV, here's all you need to know about how human metapneumovirus is different from Covid-19 and ...

Sepsis, a severe and often fatal complication of infection, is a leading cause of both acute lung injury (ALI) and acute ...

The hospitalized teen was also given three antiviral treatments, underscoring how severe H5N1 infection can be ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Medscape’s Neha Pathak, MD, and George Koob, PhD, Director of the National Institute on Alcohol Abuse and Alcoholism, break down the latest guidance on alcohol intake.

Equities research analysts at StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a note ...

About Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic diseases, oncology, and ARDS. The Company’s drug ...

As for testing, the girl's first swab at BC Children's was positive for influenza A but negative for H1 or H3 disease.

Here’s what to know about the United States’ first confirmed severe case of H5N1 avian influenza—and how to protect yourself.